Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas' Disease
Open Access
- 15 May 2014
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 370 (20), 1899-1908
- https://doi.org/10.1056/nejmoa1313122
Abstract
Current therapeutic options for Chagas' disease are limited to benznidazole and nifurtimox, which have been associated with low cure rates in the chronic stage of the disease and which have considerable toxicity. Posaconazole has shown trypanocidal activity in murine models.Keywords
This publication has 30 references indexed in Scilit:
- Safety of benznidazole use in the treatment of chronic Chagas' diseaseJournal of Antimicrobial Chemotherapy, 2012
- Antitrypanosomal Therapy for Chronic Chagas' DiseaseThe New England Journal of Medicine, 2011
- Specific chemotherapy of Chagas disease: Relevance, current limitations and new approachesActa Tropica, 2010
- Chagas diseaseThe Lancet, 2010
- Posaconazole: a new broad-spectrum antifungal agentExpert Opinion on Pharmacotherapy, 2007
- Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution.Revista da Sociedade Brasileira de Medicina Tropical, 2007
- Long-Term Cardiac Outcomes of Treating Chronic Chagas Disease with Benznidazole versus No TreatmentAnnals of Internal Medicine, 2006
- Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease.The American Journal of Tropical Medicine and Hygiene, 1998
- Antiproliferative Effects and Mechanism of Action of SCH 56592 against Trypanosoma ( Schizotrypanum ) cruzi : In Vitro and In Vivo StudiesAntimicrobial Agents and Chemotherapy, 1998
- Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infectionThe Lancet, 1996